oxazolidin-2-one has been researched along with azd0914 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (81.48) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Alm, RA; Golparian, D; Huband, M; Jacobsson, S; Jensen, JS; Mueller, J; Ohnishi, M; Unemo, M | 1 |
| Hammerschlag, MR; Huband, MD; Kohlhoff, SA | 1 |
| Alm, RA; Basarab, GS; Bradford, PA; Giacobbe, RA; Huband, MD; Johnstone, MR; Kutschke, AC; Miller, PF; Mueller, JP; Otterson, LG; Patey, SA; Potter, ME | 1 |
| Alm, RA; Gardner, H; Huband, MD; Kutschke, A; Lahiri, SD; Lewis, LA; McLaughlin, RE; Mueller, JP; Otterson, LG; Su, X; Whiteaker, JD | 1 |
| Crabb, DM; Duffy, LB; Huband, MD; Waites, KB | 1 |
| Cole, M; Fredlund, H; Jacobsson, S; Ringlander, J; Unemo, M; Wiggins, C | 1 |
| Andrews, B; Basarab, GS; Doig, P; Ehmann, DE; Fan, J; Gao, N; Kern, G; Mills, SD; Mueller, J; Palmer, T; Shapiro, AB; Sriram, S; Thresher, J; Walkup, GK | 1 |
| Alm, RA; Barvian, K; Basarab, GS; Doig, P; Galullo, V; Gardner, H; Gowravaram, M; Huband, M; Kern, GH; Kimzey, A; Kutschke, A; Lahiri, SD; Lawrence, K; McNulty, J; Morningstar, M; Mueller, JP; Newman, JV; Perros, M; Schuck, VJ; Singh, R; Tommasi, R; Vishwanathan, K; Walkup, G | 1 |
| Biedenbach, DJ; Bradford, PA; de Jonge, BL; Hackel, M; Huband, MD; Sahm, DF | 1 |
| Azam, MA; Jubie, S; Thathan, J | 1 |
| Alm, RA; Le, WJ; Li, S; Liu, YR; Mueller, JP; Rice, PA; Su, XH; Wan, C; Wang, BX | 1 |
| Chong, Y; Lee, H; Lee, K | 1 |
| Basarab, GS; Grimm, SW; Guo, J; Joubran, C; Luzietti, RA; Vishwanathan, K | 1 |
| Kirkcaldy, RD; Lawrence, K; Mueller, J; Papp, JR; Sharpe, S | 1 |
| Bradford, PA; deJonge, BL; Giacobbe, RA; Huband, MD | 1 |
| Damião Gouveia, AC; Jensen, JS; Unemo, M | 1 |
| Bristow, CC; Cristillo, AD; Dillon, JA; Dong, H; Grad, YH; Kirkcaldy, RD; Klausner, JD; Lawrence, K; Morris, SR; Nicholas, RA; Oldach, D; Rice, PA; Shafer, WM; Torrone, E; Wi, TE; Zhou, P | 1 |
| Hosagrahara, V; Lawrence, K; Mueller, JP; O'Donnell, J; Vishwanathan, K | 1 |
| Batteiger, BE; Hook, EW; Johnson, SM; Kwak, H; Lawrence, K; Long, J; Marrazzo, J; Mueller, J; Seña, AC; Taylor, SN; Wierzbicki, MR | 1 |
| Fenner, A | 1 |
| Lewis, DA | 1 |
| Alirol, E; Drusano, G; Foerster, S; Golparian, D; Neely, M; Piddock, LJV; Unemo, M | 1 |
| Kern, WV; Köser, R; Rossen, JWA; Schuster, S; Vavra, M | 1 |
| Aanensen, D; Ahlstrand, J; Cole, MJ; Day, M; Golparian, D; Jacobsson, S; Sánchez-Busó, L; Unemo, M | 1 |
| Adamson, PC; Ha, SM; Klausner, JD; Lin, EY | 1 |
| Conrad, T; Gu, K; Kankam, M; Mueller, J; Nakamura, A; Newman, LM; O'Donnell, J; Osborn, BL; Saviolakis, GA | 1 |
| Alirol, E; Bettiol, E; Delhomme, S; Gillon, JY; Luckey, A; Mueller, J; O'Brien, S; O'Donnell, J | 1 |
3 review(s) available for oxazolidin-2-one and azd0914
| Article | Year |
|---|---|
Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.
Topics: Amino Acid Sequence; Aminopyridines; Anti-Bacterial Agents; Barbiturates; Benzimidazoles; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Indazoles; Isoxazoles; Morpholines; Organophosphates; Oxazolidinones; Prodrugs; Pyrazoles; Pyrroles; Pyrrolidines; Pyrrolidinones; Quinazolinones; Quinolines; Spiro Compounds; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Urea | 2015 |
New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Drug Resistance, Bacterial; Drug Therapy, Combination; Gonorrhea; Humans; Isoxazoles; Macrolides; Morpholines; Neisseria gonorrhoeae; Neisseriaceae Infections; Oxazolidinones; Pharyngitis; Spectinomycin; Spiro Compounds; Triazoles | 2016 |
New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.
Topics: Acenaphthenes; Anti-Bacterial Agents; Barbiturates; Drug Development; Drug Resistance, Multiple, Bacterial; Gonorrhea; Heterocyclic Compounds, 3-Ring; Humans; Isoxazoles; Macrolides; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Triazoles | 2019 |
7 trial(s) available for oxazolidin-2-one and azd0914
| Article | Year |
|---|---|
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.
Topics: Adult; Animals; Anti-Bacterial Agents; Barbiturates; Disease Models, Animal; DNA Topoisomerases, Type II; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gonorrhea; Haplorhini; Humans; Isoxazoles; Male; Mice; Microbial Sensitivity Tests; Middle Aged; Models, Molecular; Molecular Conformation; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Rats; Spiro Compounds; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase II Inhibitors; Young Adult | 2015 |
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bacterial Vaccines; Barbiturates; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Gonorrhea; Group Processes; Humans; Isoxazoles; Macrolides; Microbial Sensitivity Tests; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Public Health; Sexually Transmitted Diseases; Spiro Compounds; Topoisomerase Inhibitors; Triazoles; World Health Organization | 2019 |
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Barbiturates; Biological Availability; Biotransformation; Drug Administration Schedule; Feces; Female; Gastrointestinal Absorption; Half-Life; Healthy Volunteers; Humans; Isoxazoles; Male; Morpholines; Oxazolidinones; Spiro Compounds | 2019 |
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Barbiturates; Ceftriaxone; Female; Female Urogenital Diseases; Gonorrhea; Humans; Injections, Intramuscular; Intention to Treat Analysis; Isoxazoles; Male; Male Urogenital Diseases; Microbial Sensitivity Tests; Middle Aged; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Pharyngeal Diseases; Rectal Diseases; Sexual Partners; Spiro Compounds; Treatment Outcome; Young Adult | 2018 |
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Gonorrhea; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2021 |
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
Topics: Adult; Barbiturates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fluoroquinolones; Gonorrhea; Healthy Volunteers; Heart Rate; Humans; Isoxazoles; Long QT Syndrome; Morpholines; Oxazolidinones; Spiro Compounds | 2021 |
Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Cross-Over Studies; Gonorrhea; Healthy Volunteers; Humans; Oxazolidinones | 2023 |
17 other study(ies) available for oxazolidin-2-one and azd0914
| Article | Year |
|---|---|
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Topics: Anti-Bacterial Agents; Barbiturates; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gonorrhea; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2014 |
In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Chlamydia trachomatis; Chlamydophila pneumoniae; DNA Gyrase; Doxycycline; Isoxazoles; Levofloxacin; Microbial Sensitivity Tests; Morpholines; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2014 |
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Topics: Anti-Bacterial Agents; Atypical Bacterial Forms; Barbiturates; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Nucleic Acid Synthesis Inhibitors; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2015 |
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Topics: Barbiturates; DNA Gyrase; Drug Resistance, Bacterial; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Topoisomerase II Inhibitors | 2015 |
In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Doxycycline; Humans; Isoxazoles; Levofloxacin; Microbial Sensitivity Tests; Morpholines; Mycoplasma; Mycoplasma genitalium; Mycoplasma pneumoniae; Oxazolidinones; Spiro Compounds; Ureaplasma | 2015 |
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Cefixime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Bacterial; Europe; Fluoroquinolones; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2015 |
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Topics: Anti-Bacterial Agents; Barbiturates; Ciprofloxacin; Clinical Trials as Topic; DNA; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gene Expression; Humans; Isoxazoles; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Species Specificity; Spiro Compounds; Topoisomerase II Inhibitors | 2015 |
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Topics: Anti-Infective Agents; Barbiturates; DNA Gyrase; DNA Topoisomerase IV; Gram-Negative Bacteria; Gram-Positive Bacteria; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Oxazolidinones; Spiro Compounds | 2015 |
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gene Expression; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Tetracycline; Topoisomerase II Inhibitors; Urethritis | 2016 |
Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents.
Topics: Animals; Barbiturates; DNA Topoisomerases, Type II; Dogs; Humans; Isoxazoles; Mice; Morpholines; Oxazolidinones; Rats; Spiro Compounds; Topoisomerase Inhibitors | 2017 |
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Multiple, Bacterial; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; United States; Urethritis | 2016 |
Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914.
Topics: Anti-Bacterial Agents; Bacteria; Barbiturates; Culture Media; Humans; Hydrogen-Ion Concentration; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Oxazolidinones; Reproducibility of Results; Spiro Compounds; Temperature | 2017 |
In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains.
Topics: Animals; Anti-Bacterial Agents; Barbiturates; Chlorocebus aethiops; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Mycoplasma genitalium; Oxazolidinones; Real-Time Polymerase Chain Reaction; Spiro Compounds; Vero Cells | 2018 |
Efficacy of a novel single-dose oral antibiotic for urogenital gonorrhoea.
Topics: Anti-Bacterial Agents; Barbiturates; Gonorrhea; Humans; Isoxazoles; Morpholines; Oxazolidinones; Spiro Compounds | 2019 |
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Bacterial; Drug Synergism; Isoxazoles; Microbial Sensitivity Tests; Models, Theoretical; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2019 |
New Topoisomerase Inhibitors: Evaluating the Potency of Gepotidacin and Zoliflodacin in Fluoroquinolone-Resistant Escherichia coli upon
Topics: Acenaphthenes; Anti-Bacterial Agents; Barbiturates; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Heterocyclic Compounds, 3-Ring; Isoxazoles; Morpholines; Multidrug Resistance-Associated Proteins; Oxazolidinones; Spiro Compounds; Topoisomerase Inhibitors | 2021 |
Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Bacterial; Gonorrhea; Humans; Isoxazoles; Microbial Sensitivity Tests; Morpholines; Mutation; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds | 2021 |